INM (InMed Pharmaceuticals Inc. Common Shares) Stock Analysis - News
InMed Pharmaceuticals Inc. Common Shares (INM) is a publicly traded Healthcare sector company. As of May 19, 2026, INM trades at $1.42 with a market cap of $2.12M and a P/E ratio of -0.08. INM moved +125.50% today. Year to date, INM is -39.22%; over the trailing twelve months it is -76.93%. Its 52-week range spans $0.58 to $8.27. Rallies surfaces INM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in INM news today?
InMed-Mentari Merger Secures US$290M, Funds Migraine Programs Through 2028: InMed will merge with Mentari Therapeutics in an all-stock deal valuing the combined company at US$421.4 million, with InMed shareholders holding about 1.51%. A US$290 million private placement will fund MT-001 anti-PACAP and MT-002 anti-CGRP/PACAP bispecific migraine programs through 2028, with first-in-human filings planned mid-2026 and Q1 2027.
MANCINI ALEXANDRA DIANE JANET sold 240 (~$42.312) on Jul 31, 2024.
HULL ANDREW bought 37.50K (~$14.63K) on Feb 21, 2024.
ADAMS ERIC A bought 41.60K (~$14.92K) on Feb 20, 2024.
INM Analyst Consensus
INM analyst coverage data. Average price target: $0.00.
Common questions about INM
What changed in INM news today?
InMed-Mentari Merger Secures US$290M, Funds Migraine Programs Through 2028: InMed will merge with Mentari Therapeutics in an all-stock deal valuing the combined company at US$421.4 million, with InMed shareholders holding about 1.51%. A US$290 million private placement will fund MT-001 anti-PACAP and MT-002 anti-CGRP/PACAP bispecific migraine programs through 2028, with first-in-human filings planned mid-2026 and Q1 2027.
Does Rallies summarize INM news?
Yes. Rallies summarizes INM news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is INM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INM. It does not provide personalized investment advice.
